| abstract |
The present invention, Cyclin B1 (Cyclin B1), cyclin-dependent kinase 1 (Cyclin-dependent kinase 1; CDK1), and retinoic acid receptor responder 1 (Retinoic acid receptor responder 1; RARRES1) screening method of cancer therapeutics, And as a composition for diagnosing cancer or predicting prognosis, the present inventors have studied in order to reveal molecular mechanisms for diagnosis and prognosis of cancer, according to the degree of mutual binding of RARRES1 and CDK1 or Cyclin B1 in a cancer-derived subject It was confirmed that RARRES1 is an important factor for cancer diagnosis, prognosis prediction, and treatment by confirming that it stops mitosis of cancer cells, inhibits the formation of CDK1-Cyclin B1 complex, and promotes the degradation of these proteins. Through this, CDK1 and Cyclin B1 The degree of binding is decreased, the binding degree of the RARRES1 and CDK1 or Cyclin B1 is increased, and the stability or activity of the CDK1 or Cyclin B1 protein is reduced. It is expected to be. |